Pharmacovigilance study of famciclovir in the Food and Drug administration adverse event reporting system database Authors: Runan Fang, Yang Zhou, Lu Han, Wenjing Chen, Ning Guan, Jianhong Li Published: 2024 ABSTRACT AbstractFamciclovir, mainly used to treat herpes zoster, is rapidly transforms into penciclovir when administered orally. Our study evaluated adverse events (AEs) associated with famciclovir by mining data from the publicly available Food and Drug Administration Adverse Event Reporting System (FAERS) database, providing a reference for clinical safety. Disproportionality analysis (including reported odds ratio and proportional reporting ratio) and Bayesian methods (including Bayesian Confidence Propagation Neural Network and Gamma-Poisson Shrinkage) were used to quantify the AE signals associated with famciclovir. A total of 17,652,186 case reports were obtained from the FAERS database, and 432 famiclovir-related AEs were identified. Nausea, headache, altered mental status, vomiting, and dizziness were found to be the most common Aes, corresponding to those reported in the Food and Drug Administration (FDA) drug labelling and clinical trials. Our study found some potential AEs of famciclovir that were not mentioned in the FDA drug labelling, such as toxic encephalopathy, encephalopathy, ataxia, dysarthria, dementia, cerebral infarction, tremor, purpura, skin ulcers, acute pancreatitis, rhabdomyolysis, muscle twitching, increased blood urea, lowered blood pressure, hepatitis, disease recurrence, drug interactions, and pancytopenia. Our study identified potential famciclovir AE signals, providing insights for physicians to reduce possible side effects and promote the safe implementation of the drug in clinical settings. Keywords: FAERS, Pharmacovigilance, Famciclovir, Adverse eventSubject terms: Preventive medicine, Risk factors Introduction Herpes zoster (HZ) is a common, acute, infectious viral skin disease. Clinical symptoms of HZ may not be severe; however, if not treated promptly and systematically early, they can lead to serious complications that adversely affect the patient’s life1. Therefore, antiviral therapy is critical in the management of HZ. Early and adequate antiviral therapy relieves acute symptoms, reduces disease duration, and prevents post-treatment neuralgia to a certain extent. Famciclovir ranks among the most frequently prescribed medications for HZ, with over four million prescriptions globally2. Famciclovir, once absorbed orally, rapidly transforms into penciclovir in the intestines and liver and is phosphorylated within cells infected by the varicella-zoster virus to produce a triphosphate compound with antiviral properties. The oral bioavailability of famciclovir is higher than that of acyclovir, with an oral bioavailability of 77% 3. According to reports4, oral famciclovir is the most effective treatment for acute pain and post-herpetic neuralgia associated with HZ, providing rapid relief from HZ-related pain5. This drug is widely used in the clinical setting to treat herpes simplex viral infections and acute HZ, as well as in chronic suppressive therapy for genital herpes3. The adverse effects of famciclovir commonly include headache, nausea, and diarrhoea6,7, with severe adverse effects such as hepatotoxicity and Stevens–Johnson syndrome8. According to recent meta-analysis data, the number of adverse reactions to famciclovir is low, making them unanalysable9,10. This may be because most efficacy and safety data on famciclovir were derived from clinical trials with small sample sizes and limited follow-up durations. Due to individual differences, patients using famciclovir may experience unexpected adverse events (AEs) in real-world clinical settings. Therefore, identifying unexpected adverse drug reactions (ADRs) associated with famciclovir is clinically significant. The Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) is a public, voluntary, and spontaneous reporting database used to store postmarketing drug-and biological product-related AEs and medication errors11. Compared to clinical trials, which are limited by participant selection criteria, sample size, and follow-up duration, FAERS can collect a broader range of medication experiences and identify difficult-to-capture adverse reactions through long-term monitoring, thus complementing clinical trial limitations. Therefore, this study aimed to use data mining of famciclovir AEs in the FAERS database to reveal potential safety risks and provide a reference for their rational and safe use in clinical practice. Materials and methods Data source and processing Data on famciclovir-related AEs was sourced from the ASCII files in the FAERS database, spanning from Q1 2004 to Q2 2023. The FAERS database comprises seven datasets, including patient demographics and administrative information (DEMO), drug information (DRUG), adverse event coding (REAC), patient outcomes (OUTC), report sources (RPSR), therapy start and end dates for reported drugs (THER), and indications for use (INDI). In this research, the drug and its primary component were identified as “Famciclovir.” Additionally, prior to data mining, the drug names were standardised utilising MedEx-UIMA version 1.3.8 12. We used the primary System Organ Class (SOC) and Preferred Terms (PTs) from the Medical Dictionary for Regulatory Activities (MedDRA) 26.1 to code AEs. SOC, a high-level classification in the MedDRA, groups PTs into broad categories for summarising and analysing AEs13. In the FAERS database, reported drugs are categorised into four types: Primary Suspect (PS), Secondary Suspect (SS), Concomitant (C), and Interacting (I). To enhance the accuracy of the analysis and mitigate the effects of concomitant drug use, the AE role code was retained only when the PS drug was identified as “famciclovir”14. And limited intake of famciclovir to oral route. We discovered 432 cases of AE reports with famciclovir classified as a PS drug. Figure 1 depicts the flowchart for the study. Flow diagram for famciclovir-related AE selection from the FAERS database. AE, adverse events; FAERS, Food and Drug Administration Adverse Event Reporting System; DEMO, demographics and administrative information; REAC, adverse event coding; PS, primary suspect; PT, preferred term. Statistical analysis This study employs disproportionality analysis and Bayesian methods to investigate the potential causal relationship between famciclovir and its adverse reactions. Disproportionality analysis facilitates the comparison of AE occurrence ratios between the target drug and all others. This analysis incorporates the reported odds ratio (ROR) and the proportional reporting ratio (PRR)15. Bayesian methods comprise Bayesian confidence propagation neural network and Gamma Poisson Shrinkage, offering lower sensitivity and greater specificity compared with other methodologies16,17. To enhance the credibility of the analysis of the correlation between drugs and AEs and to validate the results from multiple perspectives, this study adopted the above four algorithms. Higher values indicate a stronger signal strength, suggesting a potentially stronger association between the target drug and AEs. Meeting the criteria of at least one of the four algorithms should be regarded as a positive signal for drug-related AEs (for specific algorithms and criteria, refer to Tables 1 and 2). Table 1Two-by-two contingency table for analysis.DrugsTarget adverse events reportedAll other adverse event casesTotalTarget drugaba + bAll other drugscdc + dTotala + cb + da + b + c + d Two-by-two contingency table for analysis. Table 2Summary of major algorithms used for signal detection.AlgorithmsEquationCriteriaRORROR = ad/bcLower limit of 95% CI > 1, N ≥ 395%CI = eln(ROR)±1.96(1/a+1/b+1/c+1/d)^0.5PPRPRR = [a(c + d)]/[c(a + b)]PRR ≥ 2, χ2 ≥ 4, N ≥ 3χ2 = [(ad-bc)^2](a + b + c + d)/[(a + b)(c + d)(a + c)(b + d)]BCPNNIC = log2[a(a + b + c + d)]/[(a + c)(a + b)]IC025 > 095%CI = eln(IC)±1.96(1/a+1/b+1/c+1/d)^0.5MGPSEBGM = a(a + b + c + d)/(a + c)/(a + b)EBGM05 > 295%CI = eln(EBGM)±1.96(1/a+1/b+1/c+1/d)^0.5 Summary of major algorithms used for signal detection. N, number of adverse event reports; 95% CI, 95% confidence interval; χ2, chi-squared; IC, information component; IC025, the lower limit of the 95% CI of the IC; E (IC), the IC expectations; V (IC), the variance of IC; EBGM, empirical Bayesian geometric mean; EBGM05, empirical Bayesian geometric mean lower 95% CI for the posterior distribution. Results Basic Characteristics of Famciclovir-Related Adverse Drug Events. Our study obtained a total of 17,652,186 reports from the FAERS database. After removing duplicate data, the total number of reports decreased to 14,926,504. Among them, there were 67,888,731 drug-related reports and 57,838,527 reports of ADRs. Finally, we identified 432 AE reports related to famciclovir as the PS, with 1,317 cases of PT induced by famciclovir as the PS. Within these reports, AEs were higher in women than in men (59.72% vs. 34.49%). In terms of age, the older population (≥ 65 years) comprised the highest proportion (46.3%). Most reports were from consumers (40.74%) rather than doctors (12.5%), pharmacists (6.48%), or other healthcare professionals (16.67%). Many reports (55.56%) did not specify the region of origin, but Japan had the highest rate (28.94%), followed by the United States (7.41%). Among the reported clinical outcomes, serious outcomes were the most common (50.22%), followed by hospitalisations (39.82%) and life-threatening situations (3.98%). Additionally, the onset time of famciclovir’s adverse reactions predominantly had a median of 2 days (interquartile range 0.00–5.5), with the majority happening within 1–7 days (43.53%), and the next most common timeframe was within 24 h (21.76%). HZ (61.20%) was the most frequently reported indication (Table 3). Table 3Clinical characteristics of reports with famciclovir from the FAERS database.CharacteristicsCase number (% of Total case Reports)GenderFemale258(59.72)Male149(34.49)Unknown25(5.79) Age < 186(1.39)18–65133(30.79)>=65200(46.30)Unknown93(21.53) Reporter Physician54(12.50) Characteristics Case number (% of Total case Reports) Pharmacist28(6.48)Other health-professional72(16.67)Consumer176(40.74)Unknown102(23.61) Reported countries(top five) Japan125(28.94)United States32(7.41)7(1.62)United Kingdom7(1.62)Unknown240(55.56) Serious outcomes Hospitalization180(39.82)Life threatening18(3.98)Disability15(3.32)Death11(2.43)Required intervention to Prevent Permanent Impairment/Damage1(0.22)Other serious227(50.22) Time to AE (days) < 174(21.76)1–7148(43.53)7–1427(7.94)14–2814(4.12)>=2820(5.88)Unknown57(16.76) Indications(top five) Herpes zoster265(61.20)Herpes simplex34(7.85)Product used for unknown Indication19(4.39)Oral herpes14(3.23)Unknown49(11.32) Clinical characteristics of reports with famciclovir from the FAERS database. Signal mining of famciclovir. This research examined reports of AEs associated with famciclovir, covering adverse reactions across 22 SOCs (Table 4). Significant SOCs that met at least one indicator criterion were nervous system diseases, hepatobiliary disorders, renal and urinary disorders, skin and subcutaneous tissue disorders, and investigations. At the PT level, this research utilised four algorithms to analyse ADRs and assess their adherence to various screening criteria, yielding 126 PTs. Among these, the top 65 PTs were listed based on ROR values, meeting at least one of the four algorithms. Tables 4 and 5 show 14 SOCs and 65 PTs. Regarding the number of cases, the most frequent PTs associated with famciclovir were nausea, headache, altered mental status, vomiting, and dizziness. When ordered by ROR value and information component (IC) signal strength, the most prominent were altered state of consciousness (n = 28, ROR 61.64, PRR 60.32, IC 5.91, empirical Bayesian geometric mean [EBGM] 60.2), toxic encephalopathy (n = 5, ROR 49.89, PRR 49.7, IC 5.63, EBGM 49.62), herpes simplex (n = 4, ROR 27.67, PRR 27.59, IC 4.78, EBGM 27.56), petit mal epilepsy (n = 3, ROR 25.18, PRR 25.13, IC 4.65, EBGM 25.11), and purpura (n = 4, ROR 18.23, PRR 18.18, IC 4.18, EBGM 18.17). Notably, adverse signals not mentioned in the FDA drug labelling (https://www.fda.gov/) included toxic encephalopathy, encephalopathy, ataxia, dysarthria, dementia, cerebral infarction, tremor, purpura, skin ulcers, acute pancreatitis, rhabdomyolysis, muscle twitching, increased blood urea, lowered blood pressure, hepatitis, disease recurrence, drug interactions, and pancytopenia. Table 4Signal strength of famciclovir adverse events at the SOC level in the FAERS database.System organ class (SOC)Case ReportsROR(95% CI)PRR(95% CI)χ2IC(IC025)EBGM(EBGM05)Nervous system disorders*2552.43(2.12, 2.79)2.15(1.91, 2.42)172.551.1(0.91)2.15(1.92)Hepatobiliary disorders*292.43(1.68, 3.51)2.4(1.69, 3.42)23.791.26(0.74)2.4(1.76)Renal and urinary disorders*411.69(1.24, 2.3)1.66(1.24, 2.23)11.090.74(0.29)1.66(1.28)Skin and subcutaneous tissue disorders*1161.62(1.34, 1.96)1.57(1.32, 1.87)25.220.65(0.37)1.57(1.34)Investigations*1181.44(1.19, 1.75)1.4(1.17, 1.67)14.630.49(0.22)1.4(1.2)Endocrine disorders41.22(0.46, 3.26)1.22(0.46, 3.25)0.160.29(−0.98)1.22(0.54)Ear and labyrinth disorders71.2(0.57, 2.52)1.2(0.57, 2.53)0.230.26(−0.74)1.2(0.64)Blood and lymphatic system disorders271.2(0.82, 1.75)1.19(0.82, 1.73)0.860.25(−0.29)1.19(0.87)Psychiatric disorders921.19(0.97, 1.48)1.18(0.97, 1.44)2.690.24(−0.06)1.18(0.99)Gastrointestinal disorders1351.17(0.98, 1.39)1.15(0.98, 1.35)2.890.2(−0.05)1.15(0.99)Eye disorders250.92(0.62, 1.37)0.92(0.62, 1.36)0.16−0.11(−0.67)0.92(0.66)Respiratory, thoracic and mediastinal disorders580.89(0.69, 1.16)0.9(0.7, 1.16)0.69−0.15(−0.53)0.9(0.72)Cardiac disorders310.84(0.59, 1.2)0.84(0.59, 1.2)0.95−0.25(−0.75)0.84(0.62)Immune system disorders110.72(0.4, 1.31)0.73(0.41, 1.31)1.15−0.46(−1.28)0.73(0.44)Metabolism and nutrition disorders200.69(0.44, 1.07)0.69(0.45, 1.06)2.83−0.53(−1.16)0.69(0.48)General disorders and administration site conditions1700.67(0.57, 0.79)0.72(0.63, 0.83)23.56−0.48(−0.71)0.72(0.63)Vascular disorders200.66(0.42, 1.02)0.66(0.43, 1.02)3.48−0.59(−1.21)0.66(0.46)Musculoskeletal and connective tissue disorders470.65(0.49, 0.87)0.66(0.5, 0.87)8.43−0.59(−1.01)0.66(0.52)Pregnancy, puerperium and perinatal conditions40.63(0.24, 1.69)0.63(0.24, 1.68)0.85−0.66(−1.93)0.63(0.28)Infections and infestations430.62(0.45, 0.84)0.63(0.47, 0.85)9.93−0.67(−1.1)0.63(0.49)Injury, poisoning and procedural complications270.22(0.15, 0.32)0.24(0.17, 0.35)72.36−2.07(−2.61)0.24(0.17)Neoplasms benign, malignant and unspecified50.16(0.07, 0.39)0.16(0.07, 0.39)21.67−2.6(−3.76)0.16(0.08) Signal strength of famciclovir adverse events at the SOC level in the FAERS database. Table 5Signal strength of famciclovir reports at the PT level in the FAERS database.System organ class (SOC)Preferred terms (PTs)CasereportsROR(95% CI)PRR(95% CI)χ2IC(IC025)EBGM(EBGM05)Nervous system disordersAltered state of consciousness2861.64(42.37, 89.67)60.32(41.57, 87.54)1630.745.91(5.38)60.2(43.99)Toxic encephalopathy549.89(20.71, 120.14)49.7(20.57, 120.06)238.215.63(4.47)49.62(23.78)Petit mal epilepsy325.18(8.11, 78.23)25.13(8.06, 78.32)69.454.65(3.23)25.11(9.73)Encephalopathy1018.05(9.69, 33.64)17.92(9.57, 33.55)159.764.16(3.31)17.91(10.64)Ataxia310.5(3.38, 32.61)10.48(3.36, 32.66)25.723.39(1.97)10.48(4.06)Depressed level of consciousness88.64(4.31, 17.32)8.59(4.33, 17.06)53.693.1(2.16)8.59(4.8)Loss of consciousness196.23(3.96, 9.81)6.16(3.92, 9.67)82.232.62(1.98)6.15(4.21)Dysarthria55.6(2.32, 13.47)5.58(2.31, 13.48)18.792.48(1.32)5.58(2.67)Dementia35.37(1.73, 16.66)5.36(1.72, 16.71)10.632.42(1)5.36(2.08)Cerebral infarction35.14(1.66, 15.97)5.13(1.65, 15.99)9.992.36(0.94)5.13(1.99)Lethargy53.63(1.51, 8.74)3.62(1.5, 8.74)9.51.86(0.7)3.62(1.74)Syncope62.55(1.14, 5.68)2.54(1.14, 5.67)5.621.35(0.27)2.54(1.3)Tremor92.24(1.16, 4.31)2.23(1.17, 4.26)6.111.16(0.26)2.23(1.29)Headache322.19(1.54, 3.11)2.16(1.55, 3.01)20.151.11(0.61)2.16(1.61)Dizziness252.15(1.45, 3.2)2.13(1.44, 3.15)15.111.09(0.53)2.13(1.53)Infections and infestationsHerpes simplex427.67(10.36, 73.87)27.59(10.35, 73.51)102.414.78(3.52)27.56(12.12)Oral herpes37.35(2.37, 22.81)7.33(2.35, 22.85)16.42.87(1.46)7.33(2.84)Herpes zoster43.09(1.16, 8.25)3.08(1.16, 8.21)5.641.62(0.36)3.08(1.36)Skin and subcutaneous tissue disordersPurpura418.23(6.83, 48.66)18.18(6.82, 48.44)64.94.18(2.92)18.17(7.99) System organ class (SOC) Preferred terms (PTs) Case reports ROR (95% CI) PRR (95% CI) χ2 IC (IC025) EBGM (EBGM05) Skin and subcutaneous tissue disordersErythema multiforme313.29(4.28, 41.29)13.27(4.26, 41.36)34.023.73(2.31)13.26(5.14)Drug eruption410.37(3.89, 27.69)10.34(3.88, 27.55)33.763.37(2.1)10.34(4.55)Angioedema87.62(3.8, 15.28)7.58(3.82, 15.05)45.732.92(1.98)7.58(4.24)Blister75.71(2.71, 11.99)5.68(2.7, 11.96)27.022.51(1.5)5.68(3.05)Skin ulcer35.08(1.64, 15.78)5.07(1.63, 15.8)9.822.34(0.93)5.07(1.97)Rash erythematous33.1(1, 9.62)3.09(0.99, 9.63)4.261.63(0.21)3.09(1.2)Urticaria92.4(1.24, 4.62)2.39(1.25, 4.56)7.271.25(0.36)2.39(1.38)Gastrointestinal disordersHyperchlorhydria317.9(5.76, 55.59)17.86(5.73, 55.67)47.724.16(2.74)17.85(6.92)Pancreatitis acute35.95(1.92, 18.49)5.94(1.91, 18.51)12.342.57(1.15)5.94(2.3)Vomiting262.45(1.66, 3.61)2.42(1.67, 3.51)21.781.27(0.72)2.42(1.75)Respiratory, thoracic and mediastinal disordersPharyngeal oedema612.44(5.58, 27.74)12.38(5.54, 27.65)62.783.63(2.56)12.38(6.33)Musculoskeletal and connective tissue disordersRhabdomyolysis1211.93(6.75, 21.06)11.82(6.7, 20.87)118.963.56(2.77)11.82(7.35)Muscle twitching35.32(1.71, 16.5)5.31(1.7, 16.55)10.482.41(0.99)5.3(2.06)InvestigationsBlood alkaline phosphatase increased69.92(4.45, 22.13)9.88(4.42, 22.07)47.913.3(2.23)9.88(5.05)Blood urea increased37.41(2.39, 23.01)7.4(2.37, 23.06)16.62.89(1.47)7.4(2.87)Aspartate aminotransferase increased86.35(3.17, 12.73)6.32(3.18, 12.55)35.832.66(1.71)6.32(3.53)Liver function test abnormal56.32(2.63, 15.22)6.3(2.61, 15.22)22.312.66(1.5)6.3(3.02)Alanine aminotransferase increased96.15(3.19, 11.84)6.11(3.2, 11.67)38.512.61(1.71)6.11(3.53) System organ class (SOC) Preferred terms (PTs) Case reports ROR (95% CI) PRR (95% CI) χ2 IC (IC025) EBGM (EBGM05) InvestigationsBlood bilirubin increased46.03(2.26, 16.09)6.01(2.26, 16.01)16.722.59(1.32)6.01(2.64)Blood pressure decreased85.27(2.63, 10.56)5.24(2.64, 10.41)27.492.39(1.44)5.24(2.93)Blood creatine phosphokinase increased33.94(1.27, 12.23)3.93(1.26, 12.25)6.571.98(0.56)3.93(1.52)Blood creatinine increased63.93(1.76, 8.77)3.92(1.76, 8.76)13.061.97(0.9)3.92(2)International normalised ratio increased33.64(1.17, 11.32)3.64(1.17, 11.35)5.741.86(0.45)3.64(1.41)Platelet count decreased62.52(1.13, 5.63)2.52(1.13, 5.63)5.491.33(0.26)2.52(1.29)Hepatobiliary disordersHepatitis69.89(4.44, 22.06)9.85(4.41, 22)47.723.3(2.23)9.85(5.03)Hepatic function abnormal56.24(2.59, 15.01)6.22(2.57, 15.03)21.892.64(1.48)6.21(2.98)Jaundice45.77(2.16, 15.41)5.76(2.16, 15.35)15.742.53(1.26)5.76(2.53)Liver disorder55(2.08, 12.03)4.98(2.06, 12.03)15.922.32(1.16)4.98(2.39)Eye disordersEyelid oedema39.25(2.98, 28.73)9.23(2.96, 28.77)22.023.21(1.79)9.23(3.58)Psychiatric disordersDisorientation99.09(4.72, 17.51)9.03(4.73, 17.24)64.33.17(2.28)9.03(5.22)Hallucination137.81(4.52, 13.49)7.74(4.47, 13.4)76.442.95(2.19)7.74(4.9)Delirium67.74(3.47, 17.27)7.71(3.45, 17.22)35.062.95(1.88)7.71(3.94)Middle insomnia37.24(2.33, 22.47)7.22(2.32, 22.5)16.082.85(1.44)7.22(2.8)Restlessness66.84(3.07, 15.25)6.81(3.05, 15.21)29.772.77(1.7)6.81(3.48)Abnormal behaviour54.7(1.95, 11.31)4.69(1.94, 11.33)14.512.23(1.07)4.69(2.25)Agitation52.73(1.13, 6.57)2.72(1.13, 6.57)5.461.45(0.29)2.72(1.31)Confusional state143.67(2.17, 6.22)3.64(2.14, 6.18)26.941.87(1.13)3.64(2.35)General disorders and administration site conditionsDisease recurrence56.48(2.69, 15.6)6.46(2.67, 15.61)23.092.69(1.53)6.46(3.1) System organ class (SOC) Preferred terms (PTs) Case reports ROR (95% CI) PRR (95% CI) χ2 IC (IC025) EBGM (EBGM05) General disorders and administration site conditionsSwelling face53.21(1.34, 7.74)3.21(1.33, 7.75)7.61.68(0.52)3.21(1.54)Drug interaction92.36(1.22, 4.54)2.35(1.23, 4.49)71.23(0.33)2.35(1.36)Cardiac disordersPalpitations134.77(2.76, 8.25)4.74(2.74, 8.21)38.392.24(1.48)4.74(3)Renal and urinary disordersUrinary incontinence34.48(1.44, 13.91)4.47(1.43, 13.93)8.092.16(0.74)4.47(1.73)Urinary retention33.97(1.28, 12.32)3.96(1.27, 12.34)6.641.99(0.57)3.96(1.53)Acute kidney injury103.25(1.74, 6.06)3.23(1.73, 6.05)15.451.69(0.84)3.23(1.92)Blood and lymphatic system disordersPancytopenia53.99(1.66, 9.6)3.98(1.65, 9.61)11.151.99(0.83)3.98(1.91)Thrombocytopenia62.41(1.08, 5.38)2.41(1.08, 5.38)4.941.27(0.19)2.41(1.23) Signal strength of famciclovir reports at the PT level in the FAERS database. Case reports ROR (95% CI) PRR (95% CI) IC (IC025) EBGM (EBGM05) Case reports ROR (95% CI) PRR (95% CI) IC (IC025) EBGM (EBGM05) Case reports ROR (95% CI) PRR (95% CI) IC (IC025) EBGM (EBGM05) ROR, reporting odds ratio; CI, confidence interval; PRR, proportional reporting ratio; χ2, chi-squared; IC, information component; EBGM, empirical Bayesian geometric mean; *, Indicates statistically significant signals. ROR, reporting odds ratio; CI, confidence interval; PRR, proportional reporting ratio; χ2, chi-squared; IC, information component; EBGM, empirical Bayesian geometric mean. Discussion Most clinical guidelines are based on randomised controlled trial results18. However, owing to limitations in trial design and small sample sizes, the effects of drugs on humans, particularly in terms of safety, cannot be fully elucidated in the real world. Therefore, it is crucial to pay attention to the risk signals of ADRs to assess drug safety and achieve a balance between the benefits and risks in clinical decision-making. Here, we report real-world data from the FAERS database to evaluate the post-marketing drug vigilance for famciclovir and identify potential new and important AEs. Our study analysed 1,371 adverse events (AE) reports from the FAERS database collected from various countries and regions. Famciclovir-related AEs were higher in women (59.72%) than in men (34.49%), possibly because most AE reports were related to HZ (61.89%). Research indicates that HZ occurs more frequently in women than in men19, resulting in increased dosage and frequency of famciclovir use in women. The onset of AEs from famciclovir was notably higher among older individuals (≥ 65 years) than in other age groups, correlating with an increased overall risk of contracting HZ with age20. Therefore, with the increasing clinical use of famciclovir, clinicians should be aware of famciclovir-related AEs, particularly in older adults. Disproportionality analysis has identified the most prominent and crucial signals at the SOC level: the nervous system, hepatobiliary, kidney and urinary system, and skin and subcutaneous tissue diseases, with the most frequently reported being nervous system diseases and skin and subcutaneous tissue diseases. At the PT level, notable AEs were mainly altered consciousness, toxic encephalopathy, simple herpes, minor epileptic seizures, and purpura. Toxic encephalopathy and purpura showed high signal strength and, despite their relatively low reporting frequency, deserve attention in the clinical setting. Herpes simplex shows high signal strength associated with the virus’s persistence in a latent state within host neurons and its periodic reactivation, with some reports coming from consumers. Consequently, some AEs (such as herpes simplex) may not be considered as true AEs. Additionally, certain AEs, such as toxic encephalopathy, encephalopathy, ataxia, dysarthria, dementia, cerebral stroke, tremors, purpura, skin ulcers, acute pancreatitis, rhabdomyolysis, muscle spasms, increased blood urea nitrogen, hypotension, hepatitis, disease relapse, drug interactions, and pancytopenia were reported infrequently and are not cited in medication guidelines. In general, clinical trials are considered the best source of evidence, but strict criteria and limited sample sizes often constrain the results; it is possible that these uncommon or severe AEs were under-observed. Patients with chronic kidney disease are at an increased risk of neurotoxicity with antiviral drugs21. Gales et al. suggested that administering therapeutic doses of famciclovir to older adults might precipitate new or exacerbate existing central nervous system disorders22. Currently, serious neurological disorders caused by famciclovir are underreported in clinical practice, and mechanistic studies on this subject are lacking. Our results showed that the signal intensity and frequency of neurological disorders reported for famciclovir were high at the SOC level, while an altered state of consciousness, toxic encephalopathy, and petit-mal epilepsy topped the list at the PT level. This does not mean that all these events are exclusively drug-induced; other factors, such as baseline patient characteristics, comorbidities, and concomitant medications, may have an effect. Physicians are recommended to perform a medication safety assessment before using famciclovir in specific populations, such as patients with underlying neurological conditions. The most common adverse reactions observed in this study were nausea, headache, vomiting, and dizziness, consistent with previous reports22–24. It has been suggested that most AEs caused by famciclovir (headache, nausea, vomiting, diarrhoea, and abdominal pain) are mild to moderate, with symptoms generally lasting one to two days25. Headaches often occur on the first or second day following the initial administration26, aligning with the occurrence time of adverse reactions indicated by the results of this study. While most haematological and serum chemistry changes are clinically minor, reports have shown significant alterations in serum glutamic pyruvic transaminase, amylase, serum lipase, and hypoglycaemia in some patients during treatment27. Conducting appropriate tests on patients before administering medication can facilitate the early identification and management of AEs, particularly those that are severe or potentially life-threatening. For new potential AE signals, more basic research is required to deepen our understanding of the mechanism of action. More targeted clinical trials are needed to validate the safety and efficacy of famciclovir. We analyzed the FAERS database and investigated AEs associated with famciclovir and other pertinent and significant AEs. This method effectively addresses the limitations of small sample sizes and short observation periods in clinical trials and offers a valuable perspective for monitoring and enhancing clinical drug safety. However, it must be emphasised that FAERS is a spontaneous reporting system originating from different countries and professionals. Underreporting or delayed and erroneous reporting of incomplete information may introduce bias into the measurement of disproportionate reporting28. Additionally, the data analysis excluded numerous unmeasured confounding factors, such as potential drug interactions, comorbidities, and combinations of medications that could influence AEs. Finally, disproportionality analysis only estimates signal strength, reflecting a statistical association between specific drugs and adverse reactions; therefore, causality cannot be established. Considering these limitations and other potential confounders, additional clinical studies are required to confirm these associations. Despite the limitations of the FAERS database in pharmacovigilance research, our thorough analysis and identification of unforeseen AE signals can lay the foundation for future clinical studies on famciclovir. Through a comprehensive and systematic analysis of the FAERS data, we found that famciclovir may cause unexpected and new significant AEs, such as altered state of consciousness, toxic encephalopathy, petit-mal epilepsy, and purpura. Moreover, attention should be paid to common adverse events related to the nervous system, hepatobiliary disorders, renal and urinary disorders, skin, and subcutaneous tissue disorders, and investigations. Given that our study was exploratory in nature, the findings must be validated through prospective studies. Therefore, large-scale, population-based prospective studies are needed to help determine the incidence of AEs associated with famciclovir and fully elucidate the possible biological mechanisms and risk factors for better risk management. Acknowledgements This study was supported by the Beijing Natural Science Foundation of China (Grant number No. 7232288). Author contributions R.F. and Y.Z contributed to conception , study design and analyzed data. L.H., W.C. and N.G. prepared all figures and Tables, and took responsibility for the collection, integrity and accuracy of the data. J.L., R.F. and Y.Z. wrote the main manuscript. All authors read and approved the final manuscript. Data availability Publicly available datasets were analyzed in this study. This data can be found here: All data come from the FAERS database, which is available at https://fis.fda.gov/extensions/FPD-QDE-FAERS/FPD-QDE-FAERS.html. Declarations Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Runan Fang and Yang Zhou contributed equally. References Associated Data Data Availability Statement Publicly available datasets were analyzed in this study. This data can be found here: All data come from the FAERS database, which is available at https://fis.fda.gov/extensions/FPD-QDE-FAERS/FPD-QDE-FAERS.html.